SCM
XFOR icon

Silverarc Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Silverarc Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-357,387
Closed -$1.43M – 92
2025
Q4 		$1.43M Buy
+357,387
New +$1.3M 0.2% 60

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Silverarc Capital Management's XFOR Position: Q1 2026 in Review

Silverarc Capital Management sold out of X4 Pharmaceuticals (XFOR) in Q1 2026, closing a stake of 357,387 shares — an estimated $1.43M sold.

Silverarc Capital Management first reported a position in XFOR in Q4 2025 and held it in 1 quarter. The position peaked at $1.43M in Q4 2025. 84 funds tracked by Wall St. Rank hold XFOR as of Q1 2026.

  • Silverarc Capital Management reported no remaining X4 Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 357,387 X4 Pharmaceuticals shares in Q1 2026, an estimated $1.43M.
  • Silverarc Capital Management first reported a position in X4 Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Silverarc Capital Management's X4 Pharmaceuticals position peaked at $1.43M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.